title: Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma.
authors.affiliation: Yale University School of Medicine, New Haven, CT, USA. juliet.fraser@yale.edu.
authors.forename: Juliet Fraser
authors.initials: JF
authors.lastname: Gibson
authors.forename: Francine
authors.initials: F
authors.lastname: Foss
authors.forename: Dennis
authors.initials: D
authors.lastname: Cooper
authors.forename: Stuart
authors.initials: S
authors.lastname: Seropian
authors.forename: Diana
authors.initials: D
authors.lastname: Irizarry
authors.forename: Lisa
authors.initials: L
authors.lastname: Barbarotta
authors.forename: Frederick
authors.initials: F
authors.lastname: Lansigan
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology*; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000473:pathology*; D009364:Neoplasm Recurrence, Local; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D010865:Pilot Projects; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib
keywords: cutaneous T cell lymphoma; peripheral T cell lymphoma; salvage therapy; sorafenib; tyrosine kinase inhibitor